Literature DB >> 28914415

A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure.

Tammy J Bungard1, Jay Mutch2, Bruce Ritchie3.   

Abstract

Guidelines suggest restarting warfarin at known maintenance doses, although this may result in a delay to achieving therapeutic anticoagulation. As such, we compared the time to achieve an INR ≥ 2.0 between those restarting warfarin maintenance vs loading doses after transient interruption, and the impact on protein C, S and factor II levels. Patients requiring interruption of warfarin for elective procedures without hospitalization were randomized 1:1 to receive warfarin maintenance or loading doses (1.5 times the maintenance dose for 3 days followed by pre-procedural warfarin maintenance dosing). Protein C, S and Factor II were drawn at baseline (prior to warfarin interruption), 7 and 14 days after restarting warfarin. Among 19 patients randomized to maintenance and 20 to loading doses, nearly half in each group had mechanical heart valves with gastrointestinal endoscopic procedures most commonly performed (41%). The median number of days to reach an INR ≥ 2.0 was 7.8 days in the loading and 9.0 in the maintenance group (difference between medians 1.2 days, 95% CI -3.1 to 4.9; P = 0.19). Although levels of protein C, S and factor II were lower in the loading vs maintenance dose group, all remained above that of baseline. Warfarin resumption with loading doses shortened the time to achieve a therapeutic INR by a median of 1.2 days. Prompt warfarin dose escalation should be done in response to the INR. Protein C and S remained above pre-warfarin interruption levels, implying a lack of depletion with restarting warfarin.

Entities:  

Keywords:  Periprocedural management; Protein C; Protein S; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28914415     DOI: 10.1007/s11239-017-1553-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  13 in total

Review 1.  Guidelines on oral anticoagulation with warfarin - fourth edition.

Authors:  David Keeling; Trevor Baglin; Campbell Tait; Henry Watson; David Perry; Caroline Baglin; Steve Kitchen; Michael Makris
Journal:  Br J Haematol       Date:  2011-06-14       Impact factor: 6.998

2.  Thrombotic complications of antithrombotic therapy: a paradox with implications for clinical practice.

Authors:  G E Raskob; J N George
Journal:  Ann Intern Med       Date:  1997-11-01       Impact factor: 25.391

3.  Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.

Authors:  Karen T Schultz; Tammy J Bungard
Journal:  Pharmacotherapy       Date:  2011-08       Impact factor: 4.705

4.  Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy.

Authors:  S Viganò; P M Mannucci; S Solinas; B Bottasso; G Mariani
Journal:  Br J Haematol       Date:  1984-06       Impact factor: 6.998

5.  Low-dose warfarin decreases coagulability without affecting prothrombin complex activity.

Authors:  J Holm; E Berntorp; R Carlsson; L Erhardt
Journal:  J Intern Med       Date:  1993-09       Impact factor: 8.989

Review 6.  Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates.

Authors:  Deborah Siegal; Jovana Yudin; Scott Kaatz; James D Douketis; Wendy Lim; Alex C Spyropoulos
Journal:  Circulation       Date:  2012-08-21       Impact factor: 29.690

Review 7.  Warfarin-induced changes in procoagulant and anticoagulant proteins.

Authors:  Y Stirling
Journal:  Blood Coagul Fibrinolysis       Date:  1995-07       Impact factor: 1.276

8.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

9.  Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial.

Authors:  S Schulman; H-G Hwang; J W Eikelboom; C Kearon; M Pai; J Delaney
Journal:  J Thromb Haemost       Date:  2014-06-25       Impact factor: 5.824

Review 10.  Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants.

Authors:  Megan O Nakashima; Heesun J Rogers
Journal:  Blood Res       Date:  2014-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.